Anavex Life Sciences Corp.
NASDAQ:AVXLBiotechnology
-$0.04 today
- Market cap
- $66.69M
- Beta
- 1.12
- P/E (TTM)
- -5.9
- EPS (TTM)
- -$0.45
Volume 1.06M
Average 1.39M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Anavex Life Sciences Corp.
NASDAQ:AVXL
Intrinsic Alpha fair value
Locked
Current Price
$0.72
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Erasca, Inc. NASDAQ:ERAS | $5.48B | $15.66 | Not rated | -15.3 | +398.55% |
MBX Biosciences, Inc. Common Stock NASDAQ:MBX | $2.78B | $55.94 | Not rated | -22.0 | +95.03% |
Absci Corporation NASDAQ:ABSI | $1.45B | $8.45 | Not rated | -9.4 | +186.01% |
MoonLake Immunotherapeutics NASDAQ:MLTX | $1.06B | $12.50 | Not rated | -5.4 | -20.31% |
MeiraGTx Holdings plc NASDAQ:MGTX | $881.67M | $9.18 | Not rated | -7.4 | +9.76% |
Valneva SE NASDAQ:VALN | $538.42M | $5.66 | Not rated | -2.9 | -38.62% |
REGENXBIO Inc. NASDAQ:RGNX | $505.18M | $7.64 | Not rated | -1.5 | -33.58% |
Arvinas, Inc. NASDAQ:ARVN | $446.61M | $6.82 | Not rated | -2.2 | -41.33% |
CytomX Therapeutics, Inc. NASDAQ:CTMX | $444.73M | $2.04 | Not rated | -8.8 | -48.21% |
Continue the stock analysis
Jump to another research area for this company.